ZymoGenetics Will Be Missed. How Seattle Biotech Can Recover and Thrive


I agree with Carl Weissman’s recent Xconomy column about the ZymoGenetics acquisition when he says that Seattle needs to be a place where biotech startups thrive. Unfortunately, his column didn’t put forth any novel solutions for making this happen (I know this wasn’t his point in writing the article). I am also in agreement that hand wringing doesn’t help ease the loss, but a moment of reflection here is certainly called for. I will admit to being saddened by the Bristol-Myers Squibb acquisition of ZymoGenetics and the potential loss of some 300 plus jobs from the local biotech scene. I felt just as bad (actually, worse, being a scientist myself) when their research group was previously shut down and the scientists were let go. I haven’t heard anyone suggest that the latest biotech buyouts (Trubion Pharmaceuticals and ZymoGenetics) are harbingers of doom, though they may seem that way to those who lose their jobs. However, it is naïve to think that they won’t have a negative impact in the short term. Ted’s comment in response to Carl’s piece did a fine job of capturing the painful impact that may await many of those employees.

Biotech advances flow from the well of scientific discovery. Individuals who haven’t worked in a biotech setting don’t always grasp the synergistic benefits of putting together a research team that recombines individual talents to innovate fantastic discoveries that lead to new drugs. This doesn’t happen often in the industry and is a rare and valuable thing. Many of us who competed against ZymoGenetics over the years would acknowledge that they had assembled such a team. ZymoGenetics own website points out that products that they discovered or developed (and which are currently marketed by other companies) have combined yearly sales of over $3 billion. Another example: look at the articles that have been written chronicling how Roche has bent over backwards not to perturb the research culture of the recently acquired Genentech. They recognize their valuable investment and the need to protect innovation. They are hopeful that the Genentech group will continue to produce novel drugs at their industry-leading pace. Making money investing in biotech, whether as a VC or as a stock market investor, is certainly very demanding. However, actually developing a novel drug and getting it on the market is significantly more difficult. There are numerous examples of companies that have been acquired (thereby returning money to their investors) but the drugs that they were purchased for didn’t pan out.

A quick look at the WaBio website shows only about 33 job openings at local biotech companies, with about an equal number of jobs listed for academic and other institutions. Since 2002, when Amgen bought Immunex, there have been over 3,200 layoffs at local biotech companies (not including any upcoming layoffs at ZymoGenetics or Trubion), and I would wager that a lot of these folks were unable to find employment locally. Taking their skills elsewhere did not benefit us here in Seattle. The loss of ZymoGenetics may indeed lead to new companies being formed by those with an entrepreneurial spirit, as Carl suggested. However, it will take years (if ever) for these putative new companies to employ the number of individuals who typically are let go in these acquisitions. This also assumes that these companies get VC or other financial backing, which in the current economic climate is far from guaranteed. Also, Carl suggests that acquisitions recycle liquidity to investors, but how many of those investors are actually here in Seattle? Won’t most of that money go to support ventures (and not necessarily biotech) in other parts of the U.S. and, indeed, the world?

Many of us who work in the industry use the term “biotech anchor tenant”, but the phrase is often employed without benefit of a clear definition. Given that this term may mean different things to different people, I will offer one. A biotech anchor tenant for a city or a region, to my mind, is a company that meets two general criteria: (1) it is a near constant source of at least some jobs, owing to it’s relatively large size, rate of employee turnover, growth rate, or combination of these factors, and (2) is stable in the region and is not likely to close, relocate, or be acquired. This second criteria is getting harder and harder to meet. Even Big Pharma has closed down a number of its research facilities in the past year, with significant negative effects on the communities involved. For example, Pfizer abandoned its New London, CT research campus (and moved 1,400 jobs) leaving the town devastated. And even Big Biotech (e.g. Genentech), as we now know, was not too big to be acquired. Amgen’s Helix campus here in Seattle would meet this general definition as an anchor tenant, but more significantly, I would argue that Dendreon … Next Page »

Single PageCurrently on Page: 1 2

Stewart Lyman is Owner and Manager of Lyman BioPharma Consulting LLC in Seattle. He provides strategic advice to clients on their research programs, collaboration management issues, as well as preclinical data reviews. Follow @

Trending on Xconomy

By posting a comment, you agree to our terms and conditions.

7 responses to “ZymoGenetics Will Be Missed. How Seattle Biotech Can Recover and Thrive”

  1. pugetmarco says:

    Excellent rebuttal from Stewart Lyman to Carl Weissman’s post re ZymoGenetics acquisition. Most of his points seem on target to me, but this one may be the crux:

    “Many of us who competed against ZymoGenetics over the years would acknowledge that they had assembled such a team. ZymoGenetics own website points out that products that they discovered or developed (and which are currently marketed by other companies) have combined yearly sales of over $3 billion.”

    Had ZymoGenetics’ management team done a more competent job over the years, it seems probable they would have retained some/more/most of these products for their own portfolio and then been able to a) fend off a BMY acquisition with robust product sales, b) partner as an equal, or c) been acquired with far more favorable terms.

    Unfortunately the rank and file employees (about whom Ted wrote in his response) bear the greatest brunt of poor decisions by management. This is not unique to our industry either – just consider Detroit as an example.

  2. Where to start…

    Read the company’s SEC filing SC-14D9 filed 9/15/2010 for an eye-opening description of this transaction. You don’t have to read all 100-something pages, the first 35 will suffice.

    ZGEN was 5 years from cash flow break even, less if you count likely interferon-lambda milestones. After subtracting cash on hand, the deal was a mere 11% above the 52-week high. RecoThrom was cash-flow positive by the end of this year. Q1-2011 would have returned important interferon-lambda Phase IIb data, which would almost certainly have been positive. Wall Street analysts were starting to wake up to the fact DAAs were not going to be a sole-source solution, warming to the idea of a better interferon for combination therapies.

    I have no idea what the Board was thinking. It’s clear from the SEC filing Warburg wanted to exit their shares as early as 2008, which would have hurt the stock price had they done so in the open market. ZGEN approached BMY to see if they wanted to buy Warburg’s shares, which is what started this whole mess.

    I know no investor who was uncomfortable with ZGEN’s fundamental progress. Most of our clients in the stock added here and there and thought of it as a core long-term holding. In the crazy world of dev-stage biotech investing in the public markets, this kind of patience is rare but (at least I thought until the deal was announced) deserved by this organization.

    I feel badly for the employees at Zymo. While this purchase has been described as the typical life cycle of biotechnology companies, this was something more. This was a failure of the Board to have faith in the direction of the company.

    That’s not easy for me to say. I consider a couple of the Board members friends. I’ve known management for nearly a decade as we started covering the company in 2002. Bruce Carter and Bruce Montgomery, in particular, have been influential both professionally and politically.

    I’m on record saying that watching Seattle’s small biotechs bought by other companies is no reason for hand wringing. It’s part of the a cycle in the pharmaceutical world. I’m also on record talking about the need for an anchor tenant — whether an operationally mature drug seller or significant drug manufacturing presence — as being useful for recruiting.

    This deal with ZGEN seems different, somehow. The feeling is not so much that one of our own made it to the natural exit point in the biotech business cycle, but more that one of our own was robbed from the crib.